Compare Abeona Therapeutics Inc (ABEO) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs WD 40 Company — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while WD 40 Company trades at $233.59 (market cap $3.15B). The key difference: WD 40 Company is far larger — about 7.4× Abeona Therapeutics Inc's market cap, and WD 40 Company pays a 1.74% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WDFC | |
|---|---|---|
Market Cap | $424.33M | $3.15B |
Sector | Health | Technology |
52-Week High | $7.45 | $264.91 |
52-Week Low | $4.17 | $187.52 |
Enterprise Value | $279.23M | $3.20B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
WDFC trades at $234.93, up 1.61% today, with a bullish technical outlook supported by moving averages but neutral oscillators. Recent Q2 2026 earnings beat expectations at $2.33 EPS, though Q4 2025 missed. The company maintains strong profitability with a 55.82% gross margin and 13.22% net margin, while valuation ratios like P/E of 35.64 suggest a premium. A quarterly dividend of $1.02 was declared, payable July 31, 2026.
Outlook is mixed: solid brand strength and cash flow support growth, but high input costs pressure margins. Risks include competitive threats and valuation concerns. Analyst consensus is cautious with 71.42% hold ratings. Upside hinges on margin stability and execution of clear growth strategies amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
